#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
James Fettiplace Email
VP, Lead Clinical Development . Mereo BioPharma
London,
Locationj***************@mereobiopharma.com
Primary EmailHow to contact James Fettiplace
Join and see James's contact info for free!Current Roles
Employees:
52Revenue:
$8.1MAbout
Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.Mereo BioPharma Address
1 Cavendish PlaceLondon, null
UK